Ultra-radical compartmentalized surgery in gynaecological oncology

被引:34
作者
Hoeckel, M. [1 ]
机构
[1] Univ Leipzig, Dept Obstet & Gynaecol, D-04103 Leipzig, Germany
来源
EJSO | 2006年 / 32卷 / 08期
关键词
pelvic exenteration; advanced gynaecologic cancer; recurrent gynaecologic cancer; pelvic side wall disease; embryology; local tumour spread;
D O I
10.1016/j.ejso.2006.03.040
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: To describe "ultra-radical" surgery in gynaecological oncology. This is multivisceral pelvic resection aimed at the eradication of locally advanced and recurrent gynaecologic cancer with microscopically tumour-free margins (RO). Methods: Up-dated analysis of a prospective trial evaluating oncologic outcome and treatment-related morbidity of ultra-radical compartmentalized surgery carried out by the author. Results: From 8/1996 until 9/2005 74 patients with locally advanced and recurrent gynaecologic tumours have been treated with ultraradical compartmentalized surgery. Eighteen patients with central disease underwent exenteration as multimesovisceral excision, 56 patients with pelvic side wall disease received laterally extended endopelvic resection. In 72 of the patients the tumours were removed with microscopically free margins (RO). Two patients with advanced age and extensive comorbidity respectively, died during the early postoperative period. Moderate and severe treatment-related morbidity was 66%. At a median follow-up period of 29 months (I - 112 months) 5-year overall and recurrence-free survival probabilities are 56% (95% CI: 42-69) and 56% (42-70). Conclusion: Ultra-radical compartmentalized pelvic surgery may salvage selected patients with locally advanced and recurrent gynaecologic malignancies including those with pelvic side wall disease traditionally not considered for surgical therapy. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:859 / 865
页数:7
相关论文
共 25 条
[1]   Pelvic exenteration for recurrent gynecologic malignancy: Survival and morbidity analysis of the 45-year experience at UCLA [J].
Berek, JS ;
Howe, C ;
Lagasse, LD ;
Hacker, NF .
GYNECOLOGIC ONCOLOGY, 2005, 99 (01) :153-159
[2]  
BRUNSCHWIG A, 1948, CANCER, V1, P177, DOI 10.1002/1097-0142(194807)1:2<177::AID-CNCR2820010203>3.0.CO
[3]  
2-A
[4]  
BRUNSCHWIG A, 1969, SURGERY, V65, P417
[5]   THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE [J].
CELLA, DF ;
TULSKY, DS ;
GRAY, G ;
SARAFIAN, B ;
LINN, E ;
BONOMI, A ;
SILBERMAN, M ;
YELLEN, SB ;
WINICOUR, P ;
BRANNON, J ;
ECKBERG, K ;
LLOYD, S ;
PURL, S ;
BLENDOWSKI, C ;
GOODMAN, M ;
BARNICLE, M ;
STEWART, I ;
MCHALE, M ;
BONOMI, P ;
KAPLAN, E ;
TAYLOR, S ;
THOMAS, CR ;
HARRIS, J .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :570-579
[6]  
Crowe PJ, 1999, SEMIN SURG ONCOL, V17, P152, DOI 10.1002/(SICI)1098-2388(199910/11)17:3<152::AID-SSU3>3.0.CO
[7]  
2-J
[8]  
ENKER WE, 1992, ARCH SURG-CHICAGO, V127, P1396
[9]  
Estape R, 1999, SEMIN SURG ONCOL, V16, P236, DOI 10.1002/(SICI)1098-2388(199904/05)16:3<236::AID-SSU8>3.0.CO
[10]  
2-J